Biopharmaceutical company Kinarus Therapeutics Holding AG (SIX: KNRS) revealed on Monday that data shows its KIN001 provides strong antiviral efficacy against the original SARS-CoV-2 strain of COVID-19 and variants of concern (VOC).
KIN001 is a proprietary patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
The company said its collaboration with virologists at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) showed that KIN001 almost completely blocked virus replication in multiple human cell lines for all SARS-CoV-2 strains, including VOC such as the highly infectious Delta and Omicron variants.
Kinarus added that it has received a grant of up to CHF7m from the Programme for COVID-19 medicines of the Swiss Federal Office of Public Health to support clinical development of KIN001. The first Phase 2 clinical trial of KIN001 to treat hospitalised COVID-19 patients (KINETIC) had enrolled 130 patients as of 6 June 2022. Interim data are expected to be available late in Q3 2022.
Also, a second Phase 2 trial of KIN001 to treat ambulatory COVID-19 patients (KINFAST) has received regulatory authorisation in Switzerland and Germany and will be initiated this summer.
In addition, Kinarus disclosed that it has received regulatory authorisation to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD). In preclinical testing KIN001 reduced pathological blood vessel growth (neovascularisation) in the choroid of the eye in animal models of wet AMD. AMD is the most common cause of visual impairment among elderly patients in developed countries. The company is also preparing regulatory submissions to start Phase 2 testing of KIN001 to treat idiopathic pulmonary fibrosis (IPF). KIN001 reduced inflammation and tissue fibrosis in animal models of lung disease, supporting its clinical development as an IPF treatment.
(USD1=CHF0.97)
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer